【投融资动态】津渡生科Pre-A+轮融资，融资额千万级人民币，投资方为南山战新投

Core Insights - Shenzhen Jindu Biomedical Technology Co., Ltd. has completed a Pre-A+ round financing, raising tens of millions of RMB, with participation from Nanshan Zhanxin Investment [1][2]. Financing Details - The financing round occurred on November 13, 2025, with Nanshan Zhanxin Investment as the investor [2]. - Previous financing rounds include: - Pre-A round on November 4, 2025, with undisclosed investment from Chuang Dongfang Investment [2]. - Angel+ round on October 14, 2025, raising tens of millions of RMB from HongShan Sequoia China [2]. - Angel round on November 30, 2023, with tens of millions of RMB from Xiantong Capital [2]. - Seed round on February 28, 2023, raising millions of RMB from Shenzhen Jibei Investment Partnership [2]. Company Focus - Jindu Biomedical is focused on developing multimodal medical diagnostic models, emphasizing multi-omics analysis (RNA, DNA, protein, and metabolomics) to enhance diagnostic capabilities [2]. - The first expert model, GeneLLM, is pre-trained on 23 billion sequencing sequences and 3.45 trillion base data, transforming complex biological data into precise medical decision support tools [2]. - The technology leverages research collaboration from top universities, including Oxford University, Peking University, Tsinghua University, and Beihang University, aiming to revolutionize medical diagnostics by integrating multiple omics data for comprehensive disease diagnosis [2].